Altamira Therapeutics Ltd. Sales And Marketing Expense
Altamira Therapeutics Ltd. (CYTOF) reported Sales And Marketing Expense of CHF 160.94 thousand for the 6-month period ending 2023-06-30, per its 6-K filed 2023-09-12.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:SalesAndMarketingExpense · last filed 2023-09-12
| Period end | Sales And Marketing Expense 6 month | Sales And Marketing Expense 12 month |
|---|---|---|
| 2023-06-30 | 160.94K CHF 6-K · filed 2023-09-12 | |
| 2022-12-31 | 2.38M CHF 20-F · filed 2023-05-16 | |
| 2022-06-30 | 2.13M CHF 6-K · filed 2023-09-12 | |
| 2021-12-31 | 1.50M CHF 20-F · filed 2023-05-16 |